Norovirus: Accurate detection for high-risk patients

Norovirus can't fool me!
#CaughtByQIAGEN

Immunocompromised individuals are at increased risk from norovirus

Immunocompromised individuals, including transplant recipients and people on chemotherapy, are among the most vulnerable to severe norovirus illness.

They may not be able to effectively clear the virus and can experience chronic diarrhea and other complications, like malnutrition, dehydration and renal issues (1).

Accurate, timely diagnosis can dramatically impact patient care

For immunocompromised individuals, an accurate diagnosis is paramount. Rapid, reliable detection of norovirus is crucial to make sure these patients receive the right treatment and management.

Make sure you can reliably detect norovirus

Recent peer-reviewed reports indicate that some syndromic panels can yield inaccurate results for norovirus at a higher-than-expected frequency (3).

Always consider clinical context: The results of molecular testing should always be interpreted in the context of a patient’s clinical history – especially in vulnerable patients.
Choose a reliable test: QIAstat-Dx Gastrointestinal Panel 2 shows high specificity for norovirus detection (4).

Consultant general physician Wong Jin Shyan, M.D. at Borneo Medical Center (in Sarawak, Kuching) Malaysia

QIAstat-Dx syndromic testing is a preferred choice for immunocompromised lung transplant patients

According to Laurence Armand-Lefevre, PhD, PharmD, Professor of Microbiology at University of Paris Cité and Head of the Bacteriology Department at Bichat-Claude Bernard Hospital, France:

Laurence Armand-Lefevre, PhD, PharmD, Professor of Microbiology at University of Paris Cité and Head of the Bacteriology Department at Bichat-Claude Bernard Hospital, France

"A few months after the implementation of the QIAstat‑Dx [Gastrointestinal Panel], physicians in charge of the immunocompromised lung transplant patients asked us to perform multiplex PCR tests for all their patients.

Lung transplant patients frequently have diarrhea and the physician needs to know if this diarrhea is an adverse effect of the immunosuppressive treatment, which occurs frequently, or due to the acquisition of a GI pathogen.

This test was of particular interest for them."

Stay ahead of norovirus

Find out more about our gastrointestinal test and how it can support you.

Learn more

Other targets

References

1. Haessler S, Granowitz EV. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med. 2013;368(10):971. doi:10.1056/NEJMc1301022

2. UK Health Security Agency. (2023). Norovirus: Managing outbreaks in acute and community health and social care settings. GOV.UK. https://www.gov.uk/government/publications/norovirus-managing-outbreaks-in-acute-and-community-health-and-social-care-settings

3. Caza M, Kuchinski K, Locher K, et al. Investigation of suspected false positive norovirus results on a syndromic gastrointestinal multiplex molecular panel. J Clin Virol. 2024;175:105732. doi:10.1016/j.jcv.2024.105732

4. QIAstat-Dx Gastrointestinal Panel 2 Instructions for Use. November, 2024.

In some cases, data cited pertains to the use of a device from another manufacturer.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).